Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p (RASmiR)
Latest Information Update: 19 Jun 2024
At a glance
- Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms RASmiR
- 19 Jun 2024 Status changed from recruiting to discontinued.
- 23 Jul 2019 New trial record